ReviewCureus2026
Systematic Review Evaluating the Effects of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use on the Postoperative Outcomes of Patients Undergoing Arthroplasty Procedures.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used for weight loss and may therefore have a role in preoperative optimisation for arthroplasty candidates. However, their effect on arthroplasty outcomes remains unclear. This systematic review aims to evaluate existing evidence on preoperative GLP-1 RA use and postoperative outcomes following joint arthroplasty, and to identify priorities for future research and perioperative optimisation. A systematic literature search of PubMed, Embase, ClinicalTrials.gov and the Cochrane Library was conducted for articles published from inception to 29th July 2025, using terms related to GLP-1 RAs and arthroplasty, in accordance with the PRISMA 2020 guidelines. Studies were included if they assessed postoperative outcomes in adult patients undergoing arthroplasty with documented preoperative GLP-1 RA use. Data were extracted on study design, participant characteristics, GLP-1 RA use, arthroplasty procedure, outcome measures, duration of follow-up, and key results. Fifteen retrospective studies met the inclusion criteria, comprising a total of 39,355 patients undergoing hip, knee or shoulder arthroplasty. Nine studies reported more favourable postoperative outcomes among GLP-1 RA users, three showed mixed results, two predominantly reported worse outcomes, and one found no significant difference. The most frequently reported favourable associations were lower periprosthetic joint infection and hospital readmission rates following hip and knee arthroplasty, particularly among individuals with diabetes or morbid obesity, although results were not uniform across studies. In contrast, evidence relating to shoulder arthroplasty outcomes was limited and showed greater variability. Preoperative GLP-1 RA use has been associated with lower rates of periprosthetic joint infection and readmission in several retrospective database studies, particularly in diabetic and morbidly obese arthroplasty populations; however, the overall certainty of evidence is low due to non-randomised designs, heterogeneity and risk of bias. These findings should be considered hypothesis-generating, and well-designed prospective studies and randomised controlled trials are required to establish the role of GLP-1 RAs in preoperative optimisation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.